BACKGROUND: Evidence suggests that fatigue may be a greater problem for cancer survivors than people without cancer. The present study sought to determine whether fatigue was greater in women who had completed treatment for early-stage breast cancer relative to a demographically matched comparison group of women with no cancer history. METHODS: As part of a larger study, women with stage 0-II breast cancer were recruited before the start of chemotherapy and radiotherapy (n = 100) or radiotherapy only (n = 121). Fatigue was assessed at the end of treatment and 2, 4, and 6 months later. An age- and geographically matched sample of women with no history of cancer was recruited and assessed for comparison purposes. RESULTS: Relative to comparison subjects, breast cancer survivors reported more days of fatigue in the past week at all 4 study assessments (P < .05). These differences appeared to be clinically meaningful in that a greater percentage of patients than nonpatients earned scores in the abnormal range on this measure at each assessment (P < .05). Additional analyses indicated that differences in fatigue between patients and comparison subjects were attributable primarily to heightened fatigue in women who received both chemotherapy and radiotherapy. CONCLUSIONS: Findings suggest that fatigue is a greater problem for breast cancer survivors in the 6 months after completion of chemotherapy than for women with no cancer history. Future research should include longer-term follow-up to determine the persistence of fatigue in this population of survivors.
BACKGROUND: Evidence suggests that fatigue may be a greater problem for cancer survivors than people without cancer. The present study sought to determine whether fatigue was greater in women who had completed treatment for early-stage breast cancer relative to a demographically matched comparison group of women with no cancer history. METHODS: As part of a larger study, women with stage 0-II breast cancer were recruited before the start of chemotherapy and radiotherapy (n = 100) or radiotherapy only (n = 121). Fatigue was assessed at the end of treatment and 2, 4, and 6 months later. An age- and geographically matched sample of women with no history of cancer was recruited and assessed for comparison purposes. RESULTS: Relative to comparison subjects, breast cancer survivors reported more days of fatigue in the past week at all 4 study assessments (P < .05). These differences appeared to be clinically meaningful in that a greater percentage of patients than nonpatients earned scores in the abnormal range on this measure at each assessment (P < .05). Additional analyses indicated that differences in fatigue between patients and comparison subjects were attributable primarily to heightened fatigue in women who received both chemotherapy and radiotherapy. CONCLUSIONS: Findings suggest that fatigue is a greater problem for breast cancer survivors in the 6 months after completion of chemotherapy than for women with no cancer history. Future research should include longer-term follow-up to determine the persistence of fatigue in this population of survivors.
Authors: Kristine A Donovan; Paul B Jacobsen; Michael A Andrykowski; Erin M Winters; Lodovico Balducci; Uzma Malik; Daniel Kenady; Patrick McGrath Journal: J Pain Symptom Manage Date: 2004-10 Impact factor: 3.612
Authors: D M Hann; P B Jacobsen; L M Azzarello; S C Martin; S L Curran; K K Fields; H Greenberg; G Lyman Journal: Qual Life Res Date: 1998-05 Impact factor: 4.147
Authors: Kristin M Phillips; Heather S Jim; Brent J Small; Christine Laronga; Michael A Andrykowski; Paul B Jacobsen Journal: Cancer Date: 2011-12-12 Impact factor: 6.860
Authors: Michael A Andrykowski; Jessica L Burris; Erin Walsh; Brent J Small; Paul B Jacobsen Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544
Authors: Jennifer M Jones; Karin Olson; Pamela Catton; Charles N Catton; Neil E Fleshner; Monika K Krzyzanowska; David R McCready; Rebecca K S Wong; Haiyan Jiang; Doris Howell Journal: J Cancer Surviv Date: 2015-04-16 Impact factor: 4.442
Authors: Julienne E Bower; Patricia A Ganz; Michael R Irwin; Steven Castellon; Jesusa Arevalo; Steven W Cole Journal: J Clin Oncol Date: 2013-03-25 Impact factor: 44.544
Authors: Ann M Berger; Brett R Kuhn; Lynne A Farr; Susanna G Von Essen; Julie Chamberlain; James C Lynch; Sangeeta Agrawal Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544